3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
18
Neoplasm Metastasis
8
Esophageal Neoplasms
8
Carcinoma, Hepatocellular
7
Melanoma
6
Lung Neoplasms
6
Neoplasms
5
Breast Neoplasms
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Recurrence
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Nasopharyngeal Carcinoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Breast Neoplasms, Male
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms
1
Pleural Mesothelial Neoplasm
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Immunotherapy
×
1 year
×
Clear all
NCT07259473
2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
15 enrolled